Perform Another (Advanced) Search

1.  CenterWatch: New Medical Therapies in Disease Category (232), Aspergillosis
...CenterWatch: New Medical Therapies in Disease Category (232), Aspergillosis Aspergillosis Patient Medical Areas • Otolaryngology • Pulmonary/Respiratory Diseases October 15, 2007 Merck announced positive interim results ...
View Page

2.  Study Posting (2246) Trial #117754, Fungal Infections, Duarte, CA
...Trial Information Fungal Antigens and Antifungal Response For the Patients S uspected or Diagnosed with Aspergillosis   You have been asked to participate in this research study because you are undergoing cancer ...
...treatment such as chemotherapy or bone marrow transplantation and have been suspected or diagnosed with aspergillosis (a fungal infection). The purpose of this research is to study samples of blood, fluid ...
View Page

3.  CenterWatch New Medical Therapies™ in Pulmonary/Respiratory Diseases
...New Medical Therapies™ in Pulmonary/Respiratory Diseases Pulmonary/Respiratory Diseases Allergies & Asthma Allergy Allergy (Pediatric) Aspergillosis Asthma Bacterial Infections Bronchiectasis Bronchitis Chronic Bronchitis Common Cold COPD (Chronic Obstructive Pulmonary Disease) Cystic ...
View Page

4.  CenterWatch New Medical Therapies™ in Otolaryngology
...CenterWatch New Medical Therapies™ in Otolaryngology Otolaryngology Acute Rhinitis Allergies & Asthma Allergy Aspergillosis Auditory Loss and Deafness Esophageal Cancer Oral Candidiasis Otitis Media Pharyngitis Pneumonia Sinus Infections Strep ...
View Page

5.  Newly Approved Drug Therapies (696) Cancidas, Merck,
...in more than a decade. This medication is approved for the intravenous treatment of invasive aspergillosis in patients who have not responded to standard antifungal therapies. Aspergillosis is a life-threatening fungal infection most commonly seen in cancer patients, organ and bone ...
View Page

6.  Newly Approved Drug Therapies (784) Vfend (voriconazole), Pfizer,
...of deadly fungal infections. The medication is indicated for the primary treatment of acute invasive aspergillosis. It has also been approved as salvage therapy for rare but serious fungal infections caused ...
...spp. Unlike other agents, Vfend has been approved in both oral and intravenous formulations. Invasive aspergillosis is a deadly fungal infection that occurs in immune compromised patients. The number of people ...
View Page

7.  Study Posting (2246) Trial #153431, Solid Tumors, Duarte, CA
...to that of Voriconazole Alone When Used for Primary Therapy of Proven or Probable Invasive Aspergillosis You have/your child has been asked to participate in this research study because you ...
...to that of Voriconazole Alone When Used for Primary Therapy of Proven or Probable Invasive Aspergillosis ...
View Page

8.  CenterWatch: New Medical Therapies in Disease Category (332), Systemic Candidiasis
...multi-center non-comparative study enrolled subjects aged three months to 17 years with invasive aspergillosis, esophageal candidiasis or invasive candidiasis. The subjects received Cancidas at 50 mg/m(2) daily ...
...of treatment was individualized for each subject, however the mean duration for those with invasive aspergillosis was 42.7 days, 12.3 days for invasive candidiasis and 32 days for esophageal ...
View Page

9.  CenterWatch: New Medical Therapies in Disease Category (495), Oral Candidiasis
...multi-center non-comparative study enrolled subjects aged three months to 17 years with invasive aspergillosis, esophageal candidiasis or invasive candidiasis. The subjects received Cancidas at 50 mg/m(2) daily ...
...of treatment was individualized for each subject, however the mean duration for those with invasive aspergillosis was 42.7 days, 12.3 days for invasive candidiasis and 32 days for esophageal ...
View Page

10.  Study Posting (1570) Trial #156492, Cystic Fibrosis, Morristown, NJ
...colonization of their respiratory tract within the past 12 months (documented by screen laboratory) • Known aspergillosis (unless asymptomatic). Patients with invasive disease, ABPA with IGE > 500 mg/dL will be excluded ...
View Page

11.  CenterWatch Clinical Research Profile (1164) Trial #570, Creighton University Division of Allergy and Immunology, Omaha, NE
...Acute and chronic otitis media Acute and chronic urticaria Acute sinusitis Allergic asthma Allergic bronchopulmonary aspergillosis Allergic conjunctivitis Anaphylaxis Atopic dermatitis B cell immunodeficiencies Bronchitis Chronic sinusitis Common variable immunodeficiency Contact ...
View Page

12.  CenterWatch: New Medical Therapies in Disease Category (166), Allergy
...anidulafungin , an antifungal in combination with liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis infections. Results showed that the global response rate ranged from 12 to 49% at the ...
...95% confidence interval. The non-comparative, multi-center, global trial enrolled 30 subjects with invasive aspergillosis. Subjects were administered both LAmB at 3-5 mg per kg daily and anidulafungin intravenously ...
View Page

13.  CenterWatch: Immunology/Infectious Diseases Approved Drug Therapies
...of bacterial infections, Approved November 2001 Cancidas ; Merck; Intravenous infusion for the treatment of invasive aspergillosis, Approved January 2001 Peg-Intron (peginterferon alfa-2b) ; Schering-Plough; For the treatment of chronic ...
View Page

14.  CenterWatch: List of Newly Approved Drug Thearapies
...of bacterial infections, Approved November 2001 Cancidas ; Merck; Intravenous infusion for the treatment of invasive aspergillosis, Approved January 2001 Peg-Intron (peginterferon alfa-2b) ; Schering-Plough; For the treatment of chronic ...
View Page

15.  CenterWatch: Patient Notification System
...Disorders (Pediatric) Aplastic Anemia Appendicitis Arrhythmia Arthritis and Arthritic Pain Arthritis and Arthritic Pain (Pediatric) Aspergillosis Asthma Asthma (Pediatric) Astigmatism Atherosclerosis Athlete's Foot (Tinea Pedis) Athletic Injuries Atopic Dermatitis Atrial ...
View Page